News Napp launches Neulasta biosimilar in UK Napp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following
News Amgen faces first Neulasta biosimilar rival as FDA approves ... Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic.
R&D Health Innovators – Jennifer Schranz In the rare and ultra-rare disease space, the paucity of both data and patients makes everything about research and development more complicated.
R&D Inside the new world of healthcare data These days, real-world data collection is in vogue and not hard to come by in healthcare research.
